Arai M, Imai H, Koumura T, Yoshida M, Emoto K, Umeda M et al
Molecular mechanisms of cell cycle block by methionine restriction in human prostate cancer cells
Contributions of glutamate and GABA systems to the neurobiology and treatment of schizophrenia
The available evidence consists primarily of animal studies and limited early-phase human trials, with no published phase III clinical trial data demonstrating efficacy in inflammatory bowel disease (IBD).[1][2] The literature describes BPC-157 as a stable gastric pentadecapeptide that was tested in phase II clinical trials for inflammatory bowel disease (referenced as PL 14736), with reports indicating it was "safe" and had "no side effects." However, a 2025 review emphasizes that BPC-157 "has not been approved for use in standard medicine by the FDA and other global regulatory authorities due to the absence of sufficient and comprehensive clinical studies confirming its health benefits in humans."[1][3][2] The preclinical evidence is extensive but limited to animal models
Curr Treat Options Oncol
Eating an anti-inflammatory diet rich in fruits, vegetables, fatty fish, healthy oils, nuts and seeds, and antioxidants can help lower inflammation and your risk for disease
